173 related articles for article (PubMed ID: 38083755)
1. Simulating the Evolution of Signaling Signatures During CART-Cell and Tumor Cell Interactions.
Shah V; Womack J; Zamora AE; Terhune SS; Dash RK
Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-5. PubMed ID: 38083755
[TBL] [Abstract][Full Text] [Related]
2. Simulating the Evolution of Signaling Signatures during CART-Cell - Tumor Cell Interactions.
Shah V; Womack J; Zamora AE; Terhune SS; Dash RK
ArXiv; 2023 Feb; ():. PubMed ID: 36798455
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
[TBL] [Abstract][Full Text] [Related]
4. CRISPR Takes the Front Seat in CART-Cell Development.
Manriquez-Roman C; Siegler EL; Kenderian SS
BioDrugs; 2021 Mar; 35(2):113-124. PubMed ID: 33638865
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy.
Stock S; Schmitt M; Sellner L
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835562
[TBL] [Abstract][Full Text] [Related]
6. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
7. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
Lee YH; Kim CH
Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.
Ramakrishna S; Highfill SL; Walsh Z; Nguyen SM; Lei H; Shern JF; Qin H; Kraft IL; Stetler-Stevenson M; Yuan CM; Hwang JD; Feng Y; Zhu Z; Dimitrov D; Shah NN; Fry TJ
Clin Cancer Res; 2019 Sep; 25(17):5329-5341. PubMed ID: 31110075
[TBL] [Abstract][Full Text] [Related]
9. Effects of cryopreservation on chimeric antigen receptor T cell functions.
Xu H; Cao W; Huang L; Xiao M; Cao Y; Zhao L; Wang N; Zhou J
Cryobiology; 2018 Aug; 83():40-47. PubMed ID: 29908946
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
Holland EM; Yates B; Steinberg SM; Yuan CM; Wang HW; Annesley C; Shalabi H; Stroncek D; Fry TJ; Krueger J; Jacoby E; Hsieh E; Bhojwani D; Gardner RA; Maude SL; Shah NN
Transplant Cell Ther; 2023 Sep; 29(9):574.e1-574.e10. PubMed ID: 37394115
[TBL] [Abstract][Full Text] [Related]
11. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.
Panch SR; Srivastava SK; Elavia N; McManus A; Liu S; Jin P; Highfill SL; Li X; Dagur P; Kochenderfer JN; Fry TJ; Mackall CL; Lee D; Shah NN; Stroncek DF
Mol Ther; 2019 Jul; 27(7):1275-1285. PubMed ID: 31178392
[TBL] [Abstract][Full Text] [Related]
12. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Lee YG; Guruprasad P; Ghilardi G; Pajarillo R; Sauter CT; Patel R; Ballard HJ; Hong SJ; Chun I; Yang N; Amelsberg KV; Cummins KD; Svoboda J; Gill S; Chong EA; North K; Church SE; Fraietta JA; Chang WJ; Lacey SF; Lu XM; Zhang Y; Whig K; Schultz DC; Cherry S; Gerson J; Schuster SJ; Porazzi P; Ruella M
Cancer Discov; 2022 Oct; 12(10):2372-2391. PubMed ID: 35904479
[TBL] [Abstract][Full Text] [Related]
13. Driving cars to the clinic for solid tumors.
Castellarin M; Watanabe K; June CH; Kloss CC; Posey AD
Gene Ther; 2018 Jun; 25(3):165-175. PubMed ID: 29880908
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.
Guo Y; Feng K; Liu Y; Wu Z; Dai H; Yang Q; Wang Y; Jia H; Han W
Clin Cancer Res; 2018 Mar; 24(6):1277-1286. PubMed ID: 29138340
[No Abstract] [Full Text] [Related]
17. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
Front Immunol; 2021; 12():670286. PubMed ID: 34135898
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.
Feng K; Liu Y; Guo Y; Qiu J; Wu Z; Dai H; Yang Q; Wang Y; Han W
Protein Cell; 2018 Oct; 9(10):838-847. PubMed ID: 28710747
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
Cummins KD; Gill S
Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
[TBL] [Abstract][Full Text] [Related]
20. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
Ko AH; Jordan AC; Tooker E; Lacey SF; Chang RB; Li Y; Venook AP; Tempero M; Damon L; Fong L; O'Hara MH; Levine BL; Melenhorst JJ; Plesa G; June CH; Beatty GL
Mol Ther; 2020 Nov; 28(11):2367-2378. PubMed ID: 32730744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
